Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Ezetimibe and Atorvastatin Calcium Tablets (I), which will enhance the company's product line and market competitiveness [1][5]. Drug Registration Certificate Details - The drug registration certificate (Certificate No. 2025S03344) was issued by the National Medical Products Administration (NMPA) for Ezetimibe and Atorvastatin Calcium Tablets (I), which contains 10mg of Ezetimibe and 10mg of Atorvastatin Calcium per tablet [1][2]. - The drug is indicated for hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) and was first approved by the FDA in May 2013 [1][2]. R&D Investment - The total R&D investment for this drug has reached RMB 5.0458 million (unaudited) as of the date of the announcement [3]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Ezetimibe and Atorvastatin Calcium Tablets in China for the first half of 2025 was approximately RMB 8.64 million, with sales from urban public hospitals and county-level public hospitals accounting for RMB 6.74 million [4]. - Sales from urban community centers and township health clinics were RMB 1.77 million, while urban pharmacies and online pharmacies contributed RMB 0.13 million [4].

Core Viewpoint - Fangsheng Pharmaceutical has received approval from the National Medical Products Administration for the production of Indobufene Tablets, enhancing its product line in cardiovascular medications and increasing market competitiveness, although short-term sales impact on performance is expected to be limited [1] Summary by Categories Product Approval - The company has been granted a drug registration certificate for Indobufene Tablets, with a specification of 0.2g and a validity period until November 3, 2030 [1] Research and Development Investment - Cumulative R&D investment for the project has reached approximately 28.72 million yuan [1] Sales Performance - In the first half of 2025, the total sales for the drug in hospitals and retail pharmacies are projected to be 1.192 billion yuan and 266 million yuan, respectively [1] Market Impact - The approval enriches the company's cardiovascular medication product line and enhances its market competitiveness, but various factors may influence sales performance, leading to a limited short-term impact on overall performance [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodine Meper, which is expected to drive significant sales growth in the coming years [1] Group 1: Product Details - Iodine Meper is a non-ionic monomer X-ray contrast agent developed by Italy's Bracco, characterized by excellent physicochemical properties, including the lowest osmotic pressure and lower viscosity compared to similar agents at the same concentration [1] - The product is stable in its physicochemical properties and does not require the addition of chelating agents [1] - Indications for Iodine Meper include intravenous urography, CT scans, conventional angiography, and various forms of vascular imaging for both adults and children [1] Group 2: Market Potential - Iodine Meper has been included in the National Medical Insurance Class B directory, enhancing its market accessibility [1] - According to data from Minet, sales in China's three major terminal markets have been growing at double-digit rates, with projected sales exceeding 1.1 billion yuan in 2024, representing a year-on-year growth of approximately 32% [1] - In the first quarter of 2025, sales are expected to surpass 300 million yuan, with a year-on-year growth of about 39% [1]

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Alendronate Sodium Oral Solution, which is indicated for the treatment of osteoporosis in postmenopausal women and men, aimed at preventing hip and vertebral fractures [1] Company Summary - The newly approved Alendronate Sodium Oral Solution is designed to increase bone mass and prevent fractures in specific patient populations [1] - The projected sales revenue for Alendronate Sodium in 2024 across major distribution channels, including public hospitals, grassroots medical institutions, and retail pharmacies, is estimated to reach RMB 720 million [1]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Aisheng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Dydrogesterone Tablets, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug registration certificate for Dydrogesterone Tablets (10mg) was issued by the National Medical Products Administration, indicating that the drug has passed the consistency evaluation as per national policies [1]. Drug Information - Dydrogesterone is an orally absorbable synthetic progestogen, originally developed by Solvay Pharmaceuticals and approved for market in Portugal in July 1961. It was approved for sale in China in December 2002 for treating endogenous progesterone deficiency and supporting luteal function in assisted reproductive technology [1][2]. R&D Investment - As of the announcement date, Zhejiang Aisheng has invested a total of RMB 5.3716 million (approximately 0.537 million) in the research and development of this drug [2]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Dydrogesterone Tablets in China's three major terminal markets is approximately RMB 2.57 billion (approximately 25.70 million), with public hospitals accounting for RMB 2.20 billion (approximately 22.01 million), community health centers and township hospitals for RMB 61 million (approximately 0.61 million), and retail pharmacies and online pharmacies for RMB 308 million (approximately 3.08 million) [3].

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. has received the drug registration certificate for Irbesartan and Hydrochlorothiazide tablets from the National Medical Products Administration, enhancing its market competitiveness and expanding its cardiovascular product pipeline [1][5]. Drug Information - Drug Name: Irbesartan and Hydrochlorothiazide Tablets - Dosage Form: Tablets - Specification: Each tablet contains 150mg of Irbesartan and 12.5mg of Hydrochlorothiazide [1][2]. - Application: Drug registration for domestic production [2]. - Approval Validity: Until October 13, 2030 [2]. - Holder of Marketing Authorization: Ningbo Meinuo Tiankang Pharmaceutical Co., Ltd. [2]. - Manufacturing Company: Ningbo Meinuo Tiankang Pharmaceutical Co., Ltd. [2]. - Approval Conclusion: The drug meets the registration requirements as per the Drug Administration Law of the People's Republic of China [2]. Drug Indications and Market Context - Indication: Used for the treatment of primary hypertension [3]. - Composition: A combination of the angiotensin II receptor antagonist Irbesartan and the thiazide diuretic Hydrochlorothiazide, which can produce a synergistic effect in lowering blood pressure [3]. - R&D Investment: As of the announcement date, the company has invested approximately RMB 5.8747 million in research and development [3]. - Market Competition: Major approved companies for this drug in China include China National Pharmaceutical Group Corporation, Beijing Four Rings Keba Pharmaceutical Co., Ltd., and Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd. [3]. - Global Sales: The global sales of Irbesartan and Hydrochlorothiazide tablets reached USD 817 million in 2024, with sales in China amounting to USD 184 million [3]. Impact on Company - The approval of Irbesartan and Hydrochlorothiazide tablets signifies the company's qualification for production and sales in the domestic market, positively impacting its operational development and enhancing product competitiveness [5].

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary, Zhejiang Aisheng Pharmaceutical Co., Ltd., has received a drug registration certificate for Dydrogesterone tablets (10mg) from the National Medical Products Administration of China [1] Company Summary - The drug Dydrogesterone is an orally absorbable synthetic progestogen, originally developed by Solvay Pharmaceuticals, which has since been acquired by Abbott [1] - Dydrogesterone was first approved for sale in Portugal in July 1961 and was subsequently approved for the Chinese market in December 2002 [1] - The medication is used to treat conditions caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Company Summary - Crizotinib capsules are primarily used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for patients with advanced NSCLC who are positive for ROS1 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its product, Crizotinib capsules, which has been in the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Group 1 - Crizotinib capsules are primarily used for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) and for those with advanced NSCLC who are positive for ROS1 [1]

Core Viewpoint - Meinuo Pharma has received approval from the National Medical Products Administration for the production and sale of Irbesartan Hydrochlorothiazide tablets, enhancing its market competitiveness and expanding its cardiovascular product pipeline [1] Group 1 - Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Irbesartan Hydrochlorothiazide tablets [1] - The drug is indicated for the treatment of primary hypertension, which addresses a significant health issue [1] - The approval marks a significant milestone for the company, allowing it to produce and sell the drug in the domestic market [1] Group 2 - The introduction of this product is expected to positively impact the company's operational development [1] - The approval enhances the company's product offerings in the cardiovascular segment, which is crucial for growth in this therapeutic area [1]